Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 2

Status

Active not recruiting 5Terminated 4Completed 4Recruiting 2Withdrawn 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 22Thoracic 7Gastrointestinal 5Tumor-Agnostic 4Lymphoid 4Genitourinary 4CNS 4Head & Neck 3Dermatologic 3Sarcoma 2Gynecologic 2Plasma cell 1Other solid neoplasm 1Endocrine 1

Conditions

Urologic Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Metastatic Castration-Resistant Prostate Cancer 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Adenocarcinoma Of Esophagus 1

Interventions

Docetaxel 205Prednisone 151enzalutamide 128Gemcitabine 123Radiotherapy 117Sunitinib 112Cisplatin 103Leuprolide 98pembrolizumab 96Abiraterone Acetate 94bicalutamide 87Nivolumab 85Goserelin 83Sorafenib 80Paclitaxel 79Carboplatin 77Everolimus 72Bevacizumab 71Magnetic Resonance Spectroscopy 66acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 61pazopanib 56radium Ra 223 dichloride 50Ipilimumab 49Zoledronic Acid 47Cyclophosphamide 44Radiosurgery 43Filgrastim 42abiraterone 41gallium 68 PSMA-11 40Surveys and Questionnaires 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × abemaciclib × Genitourinary × Clear all
NCT05999968 2026-03-05

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Eli Lilly and Company

Phase 1 Completed
10 enrolled
Genitourinary

Prostatic Neoplasms

NCT04627064 2025-07-25

ABEMA Alone or in COMBO With MK-6482

Dana-Farber Cancer Institute

Phase 1 Completed
11 enrolled 9 charts
Genitourinary

Carcinoma, Renal Cell

NCT04408924 2024-06-25

CYCLONE 1

Eli Lilly and Company

Phase 2 Completed
44 enrolled 21 charts
Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03339843 2024-03-15

MiMe-A

Jules Bordet Institute

Phase 2 Completed
85 enrolled
GastrointestinalGenitourinaryGynecologic

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Neoplasms, Urologic Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡